التفاصيل البيبلوغرافية
| العنوان: |
Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer |
| المؤلفون: |
Rios-Doria, Eric, Abu-Rustum, Nadeem R, Alektiar, Kaled M, Makker, Vicky, Liu, Ying L, Zamarin, Dmitriy, Friedman, Claire F, Aghajanian, Carol, Ellenson, Lora H, Chiang, Sarah, Weigelt, Britta, Mueller, Jennifer J, Leitao, Mario M |
| المساهمون: |
National Institutes of Health, Cycle for Survival, Breast Cancer Research Foundation |
| المصدر: |
International Journal of Gynecologic Cancer ; page ijgc-2024-005522 ; ISSN 1048-891X 1525-1438 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2024 |
| الوصف: |
Objective We assessed the prognosis and molecular subtypes of early stage endometrioid endometrial cancer with isolated tumor cells within sentinel lymph nodes (SLNs) compared with node negative disease. Methods Patients diagnosed with stage IA, IB, or II endometrioid endometrial cancer and primary surgical management were identified from January 1, 2007 to December 31, 2019. All SLNs underwent ultrastaging according to the institutional protocol. Patients with cytokeratin positive cells, micrometastases, and macrometastases were excluded. Clinical, pathology, and molecular subtype data were reviewed. Results Overall, 1214 patients with early stage endometrioid endometrial cancer met the inclusion criteria, of whom 1089 (90%) had node negative disease and 125 (10%) had isolated tumor cells. Compared with node negative disease, the presence of isolated tumor cells had a greater association with deep myometrial invasion, lymphovascular space invasion, receipt of adjuvant therapy, and adjuvant chemotherapy with or without radiation (p<0.01). There was no significant difference in survival rates between patients with isolated tumor cells and node negative disease (3 year progression free survival rate 94% vs 91%, respectively, p=0.21; 3 year overall survival rate 98% vs 96%, respectively, p=0.45). Progression free survival did not significantly differ among patients with isolated tumor cells who received no adjuvant therapy or chemotherapy with or without radiation (p=0.31). There was no difference in the distribution of molecular subtypes between patients with isolated tumor cells (n=28) and node negative disease (n=194; p=0.26). Three year overall survival rates differed significantly when stratifying the entire cohort by molecular subtype (p=0.04). Conclusions Patients with isolated tumor cells demonstrated less favorable uterine pathologic features and received more adjuvant treatment with similar survival compared with patients with nodenegative disease. Among the available data, molecular classification did ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/ijgc-2024-005522 |
| الإتاحة: |
https://doi.org/10.1136/ijgc-2024-005522Test |
| رقم الانضمام: |
edsbas.49BE3C19 |
| قاعدة البيانات: |
BASE |
